Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia
Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy...
Gespeichert in:
| Veröffentlicht in: | Current hematologic malignancy reports 2016-08, Vol.11 (4), p.253-264 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 264 |
|---|---|
| container_issue | 4 |
| container_start_page | 253 |
| container_title | Current hematologic malignancy reports |
| container_volume | 11 |
| creator | Dias, Ajoy Kenderian, Saad J. Westin, Gustavo F. Litzow, Mark R. |
| description | Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema. |
| doi_str_mv | 10.1007/s11899-016-0326-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1799566690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1799566690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-c94b29eb039e2ae7ea8f6d5bd5f99fc6c0fa979339b164b4ad2e7117b80714e03</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7rr6A7xIj16qmTT9CHhZFr-g6MEVvIUkne527ZdJK-y_t6W6R5nDDMwzL8xDyCXQG6A0vnUAiRA-hcinAYt8OCJzCMPETxj7OD7MADNy5tyOUs6BBqdkxmKgQ4VzcvfSfGPprbdoVYt9VxjvrbOqw02Bzitqb2n6Dr10X7XbRpfKjUSK_SdWhTonJ7kqHV789gV5f7hfr5789PXxebVMfRNw3vlGcM0EahoIZApjVEkeZaHOwlyI3ESG5krEIgiEhohrrjKGMUCsExoDRxosyPWU29rmq0fXyapwBstS1dj0TkIsRBhFkRhRmFBjG-cs5rK1RaXsXgKVozQ5SZODNDlKkzDcXP3G97rC7HDxZ2kA2AS4YVVv0Mpd09t6ePmf1B_-IXcI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1799566690</pqid></control><display><type>article</type><title>Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Dias, Ajoy ; Kenderian, Saad J. ; Westin, Gustavo F. ; Litzow, Mark R.</creator><creatorcontrib>Dias, Ajoy ; Kenderian, Saad J. ; Westin, Gustavo F. ; Litzow, Mark R.</creatorcontrib><description>Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.</description><identifier>ISSN: 1558-8211</identifier><identifier>EISSN: 1558-822X</identifier><identifier>DOI: 10.1007/s11899-016-0326-1</identifier><identifier>PMID: 27101015</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acute Lymphocytic Leukemias (K Ballen ; Adult ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - therapeutic use ; Antigens, CD19 - immunology ; Antigens, CD20 - immunology ; Geriatrics/Gerontology ; Hematology ; Humans ; Immunotherapy ; Medicine ; Medicine & Public Health ; Molecular Targeted Therapy ; Oncology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Receptors, Antigen, T-Cell - genetics ; Receptors, Antigen, T-Cell - immunology ; Section Editor ; Sialic Acid Binding Ig-like Lectin 2 - immunology ; Topical Collection on Acute Lymphocytic Leukemias</subject><ispartof>Current hematologic malignancy reports, 2016-08, Vol.11 (4), p.253-264</ispartof><rights>Springer Science+Business Media New York 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-c94b29eb039e2ae7ea8f6d5bd5f99fc6c0fa979339b164b4ad2e7117b80714e03</citedby><cites>FETCH-LOGICAL-c344t-c94b29eb039e2ae7ea8f6d5bd5f99fc6c0fa979339b164b4ad2e7117b80714e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11899-016-0326-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11899-016-0326-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27101015$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dias, Ajoy</creatorcontrib><creatorcontrib>Kenderian, Saad J.</creatorcontrib><creatorcontrib>Westin, Gustavo F.</creatorcontrib><creatorcontrib>Litzow, Mark R.</creatorcontrib><title>Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia</title><title>Current hematologic malignancy reports</title><addtitle>Curr Hematol Malig Rep</addtitle><addtitle>Curr Hematol Malig Rep</addtitle><description>Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.</description><subject>Acute Lymphocytic Leukemias (K Ballen</subject><subject>Adult</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antigens, CD19 - immunology</subject><subject>Antigens, CD20 - immunology</subject><subject>Geriatrics/Gerontology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Molecular Targeted Therapy</subject><subject>Oncology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Receptors, Antigen, T-Cell - genetics</subject><subject>Receptors, Antigen, T-Cell - immunology</subject><subject>Section Editor</subject><subject>Sialic Acid Binding Ig-like Lectin 2 - immunology</subject><subject>Topical Collection on Acute Lymphocytic Leukemias</subject><issn>1558-8211</issn><issn>1558-822X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo7rr6A7xIj16qmTT9CHhZFr-g6MEVvIUkne527ZdJK-y_t6W6R5nDDMwzL8xDyCXQG6A0vnUAiRA-hcinAYt8OCJzCMPETxj7OD7MADNy5tyOUs6BBqdkxmKgQ4VzcvfSfGPprbdoVYt9VxjvrbOqw02Bzitqb2n6Dr10X7XbRpfKjUSK_SdWhTonJ7kqHV789gV5f7hfr5789PXxebVMfRNw3vlGcM0EahoIZApjVEkeZaHOwlyI3ESG5krEIgiEhohrrjKGMUCsExoDRxosyPWU29rmq0fXyapwBstS1dj0TkIsRBhFkRhRmFBjG-cs5rK1RaXsXgKVozQ5SZODNDlKkzDcXP3G97rC7HDxZ2kA2AS4YVVv0Mpd09t6ePmf1B_-IXcI</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Dias, Ajoy</creator><creator>Kenderian, Saad J.</creator><creator>Westin, Gustavo F.</creator><creator>Litzow, Mark R.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160801</creationdate><title>Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia</title><author>Dias, Ajoy ; Kenderian, Saad J. ; Westin, Gustavo F. ; Litzow, Mark R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-c94b29eb039e2ae7ea8f6d5bd5f99fc6c0fa979339b164b4ad2e7117b80714e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acute Lymphocytic Leukemias (K Ballen</topic><topic>Adult</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antigens, CD19 - immunology</topic><topic>Antigens, CD20 - immunology</topic><topic>Geriatrics/Gerontology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Molecular Targeted Therapy</topic><topic>Oncology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Receptors, Antigen, T-Cell - genetics</topic><topic>Receptors, Antigen, T-Cell - immunology</topic><topic>Section Editor</topic><topic>Sialic Acid Binding Ig-like Lectin 2 - immunology</topic><topic>Topical Collection on Acute Lymphocytic Leukemias</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dias, Ajoy</creatorcontrib><creatorcontrib>Kenderian, Saad J.</creatorcontrib><creatorcontrib>Westin, Gustavo F.</creatorcontrib><creatorcontrib>Litzow, Mark R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current hematologic malignancy reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dias, Ajoy</au><au>Kenderian, Saad J.</au><au>Westin, Gustavo F.</au><au>Litzow, Mark R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia</atitle><jtitle>Current hematologic malignancy reports</jtitle><stitle>Curr Hematol Malig Rep</stitle><addtitle>Curr Hematol Malig Rep</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>11</volume><issue>4</issue><spage>253</spage><epage>264</epage><pages>253-264</pages><issn>1558-8211</issn><eissn>1558-822X</eissn><abstract>Chemotherapy cures only a minority of adult patients with acute lymphoblastic leukemia (ALL). In addition, relapsed ALL has a poor outcome with 5-year survival as low as 7 %. Hence, there is a need to develop effective therapies to treat relapsed disease and to combine these agents with chemotherapy to improve outcomes in newly diagnosed patients. ALL cells express several antigens amenable to target therapies including CD19, CD20, CD22, and CD52. Over the last decade, there has been a surge in the development of immune therapies which target these receptors and that have induced robust responses. In this manuscript, we review these novel immune agents in the treatment of B-ALL. As these new therapies mature, the challenge going forward will be to find safe and effective combinations of these agents with chemotherapy and to determine their place in the current treatment schema.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27101015</pmid><doi>10.1007/s11899-016-0326-1</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1558-8211 |
| ispartof | Current hematologic malignancy reports, 2016-08, Vol.11 (4), p.253-264 |
| issn | 1558-8211 1558-822X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1799566690 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Acute Lymphocytic Leukemias (K Ballen Adult Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antigens, CD19 - immunology Antigens, CD20 - immunology Geriatrics/Gerontology Hematology Humans Immunotherapy Medicine Medicine & Public Health Molecular Targeted Therapy Oncology Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Receptors, Antigen, T-Cell - genetics Receptors, Antigen, T-Cell - immunology Section Editor Sialic Acid Binding Ig-like Lectin 2 - immunology Topical Collection on Acute Lymphocytic Leukemias |
| title | Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T11%3A00%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20Therapeutic%20Strategies%20in%20Acute%20Lymphoblastic%20Leukemia&rft.jtitle=Current%20hematologic%20malignancy%20reports&rft.au=Dias,%20Ajoy&rft.date=2016-08-01&rft.volume=11&rft.issue=4&rft.spage=253&rft.epage=264&rft.pages=253-264&rft.issn=1558-8211&rft.eissn=1558-822X&rft_id=info:doi/10.1007/s11899-016-0326-1&rft_dat=%3Cproquest_cross%3E1799566690%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1799566690&rft_id=info:pmid/27101015&rfr_iscdi=true |